NewTimeSpace News - As of 13:47 on January 9, 2026, Medical ETF (159828) rose 1.98%, with the latest price at 0.46 yuan. Over a longer timeframe, as of January 8, 2026, Medical ETF gained 7.82% over the past week, ranking 2nd out of 4 comparable funds in terms of gain. (The stocks listed above are index constituents only and do not constitute specific recommendations.)

In terms of liquidity, Medical ETF recorded an intraday turnover rate of 3.9% and trading volume of 84.4607 million yuan. Over a longer period, as of January 8, its average daily trading volume reached 115 million yuan over the past week.

Scale-wise, Medical ETF's latest size hit 2.136 billion yuan, hitting a three-month high and ranking 2nd out of 4 comparable funds. (Data source: Wind)

Data shows leveraged funds continue to build positions. Medical ETF received net leveraged purchases for four consecutive days, with the highest single-day net purchase reaching 5.5662 million yuan, bringing the latest margin balance to 63.6337 million yuan. (Data source: Wind)

As of January 8, Medical ETF's NAV rose 19.20% over the past year. In terms of return capability, as of January 9, 2026, since its inception, the ETF's highest monthly return was 30.02%, longest consecutive up months was 5, longest consecutive gain was 23.83%, and average return in up months was 5.85%. As of January 9, 2026, its three-month excess return over benchmark reached 1.90% annualized, ranking among the top 2 out of 4 comparable funds.

On drawdowns, as of January 9, 2026, Medical ETF's year-to-date maximum drawdown was 0.00%, with a relative benchmark drawdown of 0.02%.

In terms of fees, Medical ETF charges a management fee of 0.50% and a custody fee of 0.10%.

Regarding tracking accuracy, as of January 9, 2026, Medical ETF's year-to-date tracking error was 0.014%, indicating relatively high tracking precision among comparable funds.

Medical ETF closely tracks the CSI Healthcare Index. The CSI Healthcare Index selects listed securities of companies in the healthcare industry whose business involves medical devices, medical services, medical informatization, and other healthcare themes as index samples to reflect the overall performance of healthcare-themed listed securities.

Galaxy Securities stated that the centralized procurement quality expansion in the pharmaceutical and biotechnology industry has entered its latter half, with equal emphasis on price mechanisms and quality supervision. National centralized procurement has cumulatively covered 435 varieties, with the eleventh batch focusing on 55 clinically mature drugs. Through institutional innovation, it achieves stable clinical availability, quality assurance, bid-rigging prevention, and anti-internal involution, ensuring the clinical accessibility and standard consistency of selected products. As centralized procurement rules continue to optimize and price mechanisms become more rational, domestic leading enterprises, relying on compliance and innovation capabilities, are expected to achieve market share enhancement and structural growth.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.